Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141641 | 1.00 | HPGD (0.70) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL10176120 | 1.00 | HPGD (0.70) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4130916 | 0.82 | HPGD (1.00) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL14421623 | 0.82 | HPGD (0.71) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4130917 | 0.82 | HPGD (1.00) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4128453 | 0.82 | HPGD (0.71) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4128452 | 0.82 | HPGD (0.71) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL13931548 | 0.82 | ALDH1A1 (0.65) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL13931545 | 0.78 | HPGD (0.65) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4246544 | 0.77 | ALDH1A1 (0.69) | HPGDCA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | BETAGENON AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | BETAGENON AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009026345-A1 | THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008065409-A2 | COMBINATION FOR USE IN THE TREATMENT OF CANCER, COMPRISING TAMOXIFEN OR AN AROMATASE INHIBITOR | BETAGENON AB (SE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1906956-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN DISORDERS CAUSED BY FREE FATTY ACIDS | Betagenon AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1906955-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER | Betagenon AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007010281-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN DISORDERS CAUSED BY FREE FATTY ACIDS | BETAGENON AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010273-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER | BETAGENON AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | TBXA2R, TSHR, FOLR1 | HPGD 1015/4885CA1 2321/4885CA2 1258/4885 |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | HPGD 289/4885CA1 4311/4885CA2 4192/4885 |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | FFAR2, FFAR1, FFAR4 | HPGD 1115/4885CA1 4490/4885CA2 2570/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | HPGD 289/4885CA1 4311/4885CA2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.